AegirBio

April-June

• Total income amounted to 3,1 (1,3) MSEK.
• Loss before tax amounted to -8,4 (-16,4) MSEK.
• Cash and cash equivalents at the end of the quarter was 2,4 (36,6) MSEK.
• Earnings per share* -0,26 (-0,61) SEK.
• Equity ratio** at 30 June 2024 was -24 (31) %.

Significant events during the period April-June

• Jens Umehag joined Magnasense AB as the new Chairman of the Board, succeeding Anders Ingvarsson.
•Michael Schwartz and William Ferenczy joined the Board as new members.
• The terms and conditions of series 2023/2025 convertible loan notes, issued by Atlas Special Opportunities, were amended to extend the term and adjust conversion requirements.
• Further funding has been agreed through an additional 36 month secured MSEK 45 loan facility with Atlas Special Opportunities.
• Magnasense AB successfully completed an additional milestone in its participation in the NIH RADx Tech Program.
• The Company published a study in Multiple Sclerosis and Related Disorders journal.

Significant events after the end of the period

• Aegirbio AB changed its name to Magnasense AB, to better reflect core assets and focus.
• Melissa Grant, Associate Professor at the University of Birmingham’s School of Dentistry, joined Magnasense’s Scientific Advisory Board.
• Vicki Johnson joined Magnasense AB as interim CFO, succeeding Christel Dahlberg.

* Earnings per share: Profit for the period divided by the weighted average number of shares, which as of 2024-06-30 amounted to 31,758,392 shares before dilution. The corresponding number for the same period in the previous year was 23,913,424 shares.
** Equity ratio: Equity divided by total capital.